|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
41st Annual Anatomic Pathology Conference
Feb. 13-15, 2015 at Disney's Contemporary Resort in Orlando, Florida
You are invited to join the Florida Society of Pathologists at the 41st Annual Anatomic Pathology Conference at Disney's Contemporary Resort® in beautiful Lake Buena Vista, Florida!
Top legal minds against FDA's proposal to regulate lab tests
A new legal whitepaper authored by two of America's most prominent lawyers argues that the U.S. Food and Drug Administration's plan to regulate lab developed tests (LDTs) more similarly to traditional medical devices lacks legal justification and is therefore unlawful.
Mayo fights stricter oversight of lab tests
Proposed federal rules to require new government approval of certain tests developed in medical schools and private business laboratories have drawn cries of protest from the Mayo Clinic.
The proposed rules would for the first time make labs designing the tests prove their effectiveness to the U.S. Food and Drug Administration (FDA). Test developers also would have to formally report to the government problems that occur with the tests after they become available.
Stakeholders ask FDA to educate labs on agency thinking, terminology before finalizing LDT guidance
During the second day of a public workshop on the regulation of laboratory-developed tests (LDTs), industry stakeholders asked the U.S. Food and Drug Administration to produce several publications to better explain how they can meet the agency's requirements.
Specifically, workshop attendees requested FDA publish a paper explaining how it gauges the risk a test poses to public health; put out a document outlining the areas where the agency will harmonize its regulations with existing requirements under the Centers for Medicare & Medicaid Services; and issue another, revised LDT draft guidance before publishing a final version.
Do some clinical lab companies oversell prenatal genetic screening tests?
In response to growing concerns by consumers about the accuracy of some proprietary genetic screening assays, several media outlets have begun reporting on this sector of the clinical laboratory industry. What gives these news stories emotional punch is the fact that patients use these proprietary medical laboratory tests to make decisions that can be life-changing. In its story about these tests, the Boston Sunday Globe used the headline "Oversold prenatal tests spur some to choose abortions."
83 percent of physicians are resistant to use EHRs for clinical communications
Eighty-three percent of physicians expressed frustration using EHRs to support clinical communications due to poor EHR interoperability, limited EHR messaging capabilities and poor usability that makes it difficult to find relevant clinical data, according to a recent study by Spyglass Consulting Group. The report entitled Point of Care Communications for Physicians 2014 based on 100 doctors working in hospital‐based and ambulatory environments nationwide reveals physicians are universally (96 percent) using smartphones as their primary device to support clinical communications.
Portable 'blood test in a box' to give instant diagnoses
For most of us, a blood test begins with a needle, a syringe and the promise it will all be over quickly. But at the back end, testing blood often requires transporting the vial to a clinic, a range of laboratory equipment and trained clinicians and doctors to get an accurate result. The whole process can take days, and in some cases even weeks. But imagine if you could put the whole laboratory into a portable unit that delivered a reading immediately?
New data points to lung cancer biomarker potential for sputum microRNAs
Amid ever-increasing interest in using microRNAs as biomarkers, researchers from the University of Maryland published a new study suggesting that the small, non-coding RNAs may help in differentiating patients with early-stage lung cancer from those with non-malignant lung nodules. Non-small cell lung cancer remains the leading cause of cancer deaths in the U.S., killing an estimated 160,000 Americans last year.
GI needle biopsies do not spread cancer, study suggests
Needle biopsies of the pancreas are not associated with an increased risk for death in patients with pancreatic cancer, according to a retrospective study published online January 9 in Gut. The findings reinforce the safety of ultrasound-guided fine-needle aspiration (EUS-FNA), say the study investigators, who are all from the Mayo Clinic.
Miss an issue of Pathology Today? Click here to visit the Pathology Today archive page.
How to reduce risk during inpatient transitions
Good communication between hospitalists and primary care physicians at the time of discharge is critical to patient safety and to the reduction of risk. Historically, this communication has been "one-way" in the form of a discharge summary. Studies have shown that "[F]ollowing hospital discharges nearly half (49 percent) of hospitalized patients experience at least one medical error in medication continuity, diagnostic workup, or test follow-up."
Disclaimer: The authors, editors, and the Florida Society of Pathologists (FSP) Executive Committee affiliated with "Florida Pathology Today" e-Newsletter cannot and do not warrant the completeness, accuracy, non-infringement, merchantability, timeliness or fitness for a particular purpose of the information or views contained within this publication, or available through the links provided within articles contained within this publication.
FSP has no control over and does not officially endorse the content of the information available on the links contained in the "Florida Pathology Today" or links imbedded in articles within the "Florida Pathology Today." These links are provided as a courtesy only. Linked sites are not a part of the "Florida Pathology Today." The owners of those linked sites, and not FSP, own the intellectual property rights to the material on the linked sites. FSP cannot certify the accuracy of material published on linked sites. Additionally, the contents of this e-Newsletter and the above referenced links, including any advice, suggestions, and/or recommendations have NOT been generated as part of any professional evaluation.
The authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" e-Newsletter shall not be liable to anyone for any loss or injury caused in whole or in part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting or delivering this e-Newsletter and any information included in this e-Newsletter.
Under no circumstances will the authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" be liable to you or anyone else for any decision made or any action taken by you or anyone else in reliance on such information or view, or for any incidental, consequential, special, or similar damages even if advised of the possibility of such damages.
The above warranties are the only warranties of any kind either expressed or implied, including warranties of merchantability or fitness for any particular purpose.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063